Last reviewed · How we verify
NCT06894940: Reup
Rehabilitative Protocols in Progressive Multiple Sclerosis Treated with Anti CD20 Monoclonal Antibodies
Phase 2 trial testing Active Comparator #1 in Multiple Sclerosis in 82 participants. Completed in 30 November 2024.
30 November 2024
Quick facts
| Lead sponsor | University of Pavia |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 82 |
| Start date | 1 June 2021 |
| Primary completion | 30 November 2024 |
| Estimated completion | 30 November 2024 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Active Comparator #1 — full drug profile →
- Placebo
- Experimental — full drug profile →
Conditions studied
- Multiple Sclerosis — all drugs for Multiple Sclerosis →
Sponsor
University of Pavia
Who can join
Adults 25 to 65, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Progressive multiple sclerosis (MS) patients have usually a worsening clinical course and it remains unclear if rehabilitation can indeed slow down the progression of the disease. Recently, clinical studies demonstrated that a treatment with monoclonal antibodies against B lymphocytes can have a positive effect on the progression of disability. Therefore now the investigators have, in this phase of the disease, a treatment that can impact the clinical course, even if the effect is not complete. The present study project has the aim to verify if, in progressive MS treated with monoclonal antibodies, a high technology rehabilitative protocol added to an intensive rehabilitation program is more effective on the motor recovery, in particular of the upper limb, as compared to an intensive traditional scheme of rehabilitation and to a passive treatment therapy, Moreover, the MRI functional reorganization of the central nervous system will be evaluated as well as the duration of the rehabilitative effect.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06894940
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Active Comparator #1
Trials testing the same drug.
- NCT07218120 — In-Person Recruitment of Individuals to the Alzheimer's Prevention Trial (APT) Webstudy · NA · recruiting
- NCT06958588 — Pulsed Electromagnetic Field Therapy or Pneumatic Compression VTE Prophylaxis · Phase 4 · recruiting
- NCT07006337 — Surgical Operating Room Enhancement Curriculum for Medical Students · NA · recruiting
- NCT07006584 — Gait Reeducation Program in Older Adults · NA · completed
- NCT06801782 — Effectiveness of Attention/executivefunctions Training on Prospective Memory Abilities of Parkinson's Disease Subjects w · NA · completed
Other recruiting trials for Multiple Sclerosis
Currently open trials in the same condition.
- NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
- NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
- NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
- NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
- NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting
Other University of Pavia trials
Trials by the same sponsor.
- NCT07491536 — Ozone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis · NA · recruiting
- NCT07421128 — The Pause, Learn, and Activate Yourself (PLAY) · NA · not yet recruiting
- NCT07199712 — Ozone Therapy for Oral Mucositis in Patients Receiving Head and Neck Cancer Radio- and Chemotherapy · NA · completed
- NCT07088653 — Comparison of 0.12% Chlorhexidine and MicroRepair ABX Mouthwash in Gingivitis Management · NA · completed
- NCT07140146 — Trehalose vs Glycine Air-Polishing in Peri-Implant Mucositis Treatment · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06894940 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pavia
- Last refreshed: 25 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06894940.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing